AbbVie ABBV Mavyret — Net revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AbbVie in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbbVie's mavyret — net revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbbVie's mavyret — net revenues?
- AbbVie (ABBV) reported mavyret — net revenues of $351M in Q1 2026.
- How has AbbVie's mavyret — net revenues changed year-over-year?
- AbbVie's mavyret — net revenues increased by 14.7% year-over-year, from $306M to $351M.
- What is the long-term trend for AbbVie's mavyret — net revenues?
- Over 4 years (2021 to 2025), AbbVie's mavyret — net revenues has grown at a -6.3% compound annual growth rate (CAGR), from $1.71B to $1.32B.
- What does mavyret — net revenues mean?
- This metric represents the total net sales generated from the specific pharmaceutical product line used for the treatment of hepatitis C. It reflects the market demand, pricing power, and competitive positioning of this therapeutic asset within the company's broader infectious disease portfolio. As a mature product, revenue trends here provide insight into the lifecycle stage and cash flow contribution of the company's legacy specialty medicine offerings.